TScan Therapeutics (TCRX) Net Income (2020 - 2026)

TScan Therapeutics (TCRX) has reported Net Income for 7 consecutive years, with -$28.7 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Net Income rose 22.49% year-over-year to -$28.7 million; the TTM figure through Mar 2026 stood at -$133.2 million (up 8.32% YoY), while the FY2025 annual figure was -$219.9 million, down 52.08% from the prior year.
• Net Income rose to -$28.7 million in Q1 2026 per TCRX's latest filing, from -$31.8 million in the prior quarter.
• Across five years, Net Income topped out at -$15.1 million in Q2 2022 and bottomed at -$46.7 million in Q4 2024.
• Historically, Net Income has averaged -$27.4 million across 5 years, with a median of -$28.7 million in 2026.
• Annual changes were most pronounced in 2022 — Net Income jumped 54.13% — and 2024, when it tumbled 130.68%.
• TScan Therapeutics' Net Income stood at -$19.5 million in 2022, then fell by 3.64% to -$20.3 million in 2023, then slumped by 130.68% to -$46.7 million in 2024, then soared by 31.86% to -$31.8 million in 2025, then advanced by 9.98% to -$28.7 million in 2026.
• Business Quant data shows TCRX's Net Income at -$28.7 million in Q1 2026, -$31.8 million in Q4 2025, and -$35.7 million in Q3 2025.